KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth

As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite hitting all-time highs, investors are increasingly optimistic about future growth prospects. In this context, penny stocks—though often overlooked—remain a relevant area of interest for those seeking opportunities in smaller or newer companies. While traditionally seen as high-risk investments, certain penny stocks can offer compelling opportunities by combining balance sheet strength with long-term potential.

Top 10 Penny Stocks In The United States

Click here to see the full list of 418 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

KORU Medical Systems (KRMD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the drug delivery market both in the United States and internationally, with a market cap of $183.09 million.

Operations: The company generates revenue of $36.85 million from its Surgical & Medical Equipment segment.

Market Cap: $183.09M

KORU Medical Systems has demonstrated revenue growth, with second-quarter sales rising to US$10.19 million from US$8.43 million the previous year, and a reduced net loss of US$0.21 million compared to US$0.99 million a year ago. The company raised its full-year 2025 revenue guidance to between US$39.5 and $40.5 million, indicating confidence in continued growth despite ongoing unprofitability and negative return on equity (-27.32%). KORU's inclusion in multiple Russell indices may enhance visibility among investors, while its debt-free status and sufficient cash runway provide financial stability amid efforts to scale operations under new commercial leadership.

• Take a closer look at KORU Medical Systems' potential here in our financial health report.
• Explore KORU Medical Systems' analyst forecasts in our growth report.

AbCellera Biologics (ABCL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AbCellera Biologics Inc. focuses on discovering and developing antibody-based medicines for unmet medical needs in the United States, with a market cap of approximately $1.34 billion.

Operations: The company generates revenue primarily from its Discovery and Development of Antibodies segment, which accounted for $32.88 million.

Market Cap: $1.34B

AbCellera Biologics has shown significant revenue growth, with second-quarter earnings rising to US$17.08 million from US$7.32 million a year ago, though it remains unprofitable with a net loss of US$34.73 million for the quarter. The company is debt-free and its short-term assets of US$742.1 million surpass both short-term and long-term liabilities, indicating strong financial positioning despite ongoing losses and negative return on equity (-16.45%). Recent legal victories affirming patent validity bolster its intellectual property portfolio, while upcoming Phase 1 trials for antibody candidates ABCL575 and ABCL635 highlight potential advancements in its drug development pipeline.

• Click here to discover the nuances of AbCellera Biologics with our detailed analytical financial health report.
• Review our growth performance report to gain insights into AbCellera Biologics' future.

Design Therapeutics (DSGN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on researching, designing, developing, and commercializing small molecule therapeutic drugs for genetic diseases in the United States with a market cap of $243.74 million.

Operations: Design Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $243.74M

Design Therapeutics is a pre-revenue company focused on developing treatments for genetic diseases, with recent progress in its RESTORE-FA trial for Friedreich ataxia. The company reported a net loss of US$19.08 million for the second quarter of 2025, reflecting increased losses compared to the previous year. Despite being unprofitable and having an inexperienced management team, Design has no debt and sufficient cash runway exceeding three years. Its short-term assets significantly outweigh liabilities, providing financial stability as it addresses FDA concerns regarding its investigational new drug application while continuing clinical trials in Australia.

• Click here and access our complete financial health analysis report to understand the dynamics of Design Therapeutics.
• Learn about Design Therapeutics' future growth trajectory here.

Seize The Opportunity

• Access the full spectrum of 418 US Penny Stocks by clicking on this link.
• Searching for a Fresh Perspective? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com